C4 Therapeutics (CCCC) Cash from Investing Activities (2019 - 2026)

C4 Therapeutics' Cash from Investing Activities history runs 8 years deep, the most recent figure standing at $16.2 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 44.54% year-over-year to $16.2 million; the TTM figure through Mar 2026 stood at -$21.6 million (down 169.03% YoY), while the FY2025 annual figure was -$8.6 million, up 83.22% from the prior year.
• Cash from Investing Activities was $16.2 million for Q1 2026 at C4 Therapeutics, up from -$80.7 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $57.7 million in Q3 2023 to a low of -$80.7 million in Q4 2025.
• Historically, Cash from Investing Activities has averaged $10.2 million across 5 years, with a median of $15.1 million in 2023.
• Biggest YoY gain for Cash from Investing Activities was 2422.22% in 2025; the steepest drop was 690.59% in 2025.
• A 5-year view of Cash from Investing Activities shows it stood at $9.3 million in 2022, then jumped by 244.09% to $31.9 million in 2023, then slumped by 57.21% to $13.7 million in 2024, then tumbled by 690.59% to -$80.7 million in 2025, then jumped by 120.01% to $16.2 million in 2026.
• The last three Cash from Investing Activities figures came in at $16.2 million (Q1 2026), -$80.7 million (Q4 2025), and $4.1 million (Q3 2025), per Business Quant data.